Supplementary Figure S7

Aug 13, 2014

10 likes | 154 Views

Supplementary Figure S7. Immunohistochemical confirmation of target inhibition by rapamycin (p-S6) and dasatinib (p- Src ) in MMTV- PyMT tumor sections. Vehicle. Dasatinib. Rapamycin. Combination. H&E. 5 mm. p-S6. p- Src.

Share Presentation

Embed Code

Link

mm p
immunohistochemicalconfirmation
vehicle dasatinib rapamycin
supplementary figure s7
s6 p
target inhibition

awen

Download Presentation

Supplementary Figure S7

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplementary Figure S7 Immunohistochemicalconfirmation of target inhibition by rapamycin (p-S6) and dasatinib (p-Src) in MMTV-PyMT tumor sections Vehicle Dasatinib Rapamycin Combination H&E 5 mm p-S6 p-Src

Supplementary Figure 1

Supplementary Figure 1. MW/1000. pH. SJIA. POLY. Others. F. FI. F. KD. Q. Q. C3. AGP1. ACT. SAP. SAA. S100A8. S100A9. HP. CRP. C9. C4. APO-IV. APO-L1. AMBP. KLKB1. VDB. CFH. ATIII. A2M. ATIII. APO-E. APO-D. FGG FGB. TTR. GSN. APOA1. Figure 1. 12. 10. 8.

194 views • 7 slides

Supplementary Figure 7

A. Supplementary Figure 7.

72 views • 1 slides

Supplementary figure

IgG. Supplementary figure.

63 views • 1 slides

Supplementary Figure S1

Supplementary Figure S1. kDa. 70. 55. FLAG monomer. 40. 35. 25. Supplementary Figure S2. kDa. 250. 130. 100. 70. 55. Supplementary Figure S3.

165 views • 3 slides

Supplementary Figure S2

Supplementary Figure S2. (A). (B). (C). 8-oxo-dG. dG. 8-Cl-dG. hNEIL1. -. -. +. +. hAAG. EndoV. hOGG1. hOGG1. hOGG1. -. -. -. -. FPG. FPG. FPG. -. -. +. +. APE. 1. 1. 4. 2. 3. 2. 3. 2. 3. 4. 5. 6. 7. 8. 9. 1. 38. 38. 38. 30. 10.

111 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. 3. 2,5. 2. 1,5. 1. 0,5. 0. 6. 5. 4. 3. 2. 1. 0. A. WT with FSK+Gen. WT with FSK. lF508del with FSK+Gen. lF508del with FSK. ns. ns. ns. ns. Bicarbonate secretion ( normalized to the rate in FSK-treated F508del as 1). 10 min post peak response.

123 views • 2 slides

Supplementary Figure 2.

RCA. RVN. LCA. LVN. LCA. RVN. RJV. T. RJV. T. LVN. LJV. ARSA. E. LJV. TR. E. LSA. ARSA. TR. LSA. RCA. RSV. LSV. RSV. LSV. LBV. LBV. RL. LL. RL. LL. TD. H. H. Supplementary Figure 2.

86 views • 1 slides

Supplementary Figure S3

A. Line 1112 no treatment. Line 1112 with azadC. CTCFmutE. RBF-1. E2F. Sp1. CTCFmutE. RBF-1. E2F. Sp1. 34.3 %. 48.1 %. 0. 40. 90. 100. 0. 80. 0. 0. 40. 0. 90. 40. 50. 50. 80. 90. 80. 40. 40. 40. 40. 40. 80. 80. 0. 80. 0. CH 3 %. 0. 33. 100. 77. 0. 66.

86 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. a. b. c. a continuous schedule for 35 consecutive days. an intermittent schedule. DNA vaccination (50 ug/mouse). DNA vaccination (50 ug/mouse). A20 Lymphoma. A20 Lymphoma. Day. Day. 1. 35. 0. 14. 28. 0. 14. 28. 42. 21. 18. 35. 42. 32. 7. 4.

110 views • 3 slides

Supplementary Figure S7

A. MIM-R-GFP. 100. 80. 60. 40. Lung metastasis (14 days). 20. MIM-R-ILEI. 0. MIM-R -GFP. MIM-R -GFP -dnP. MIM-R -ILEI. MIM-R -ILEI -dnP. >100 cells. 50-100 cells. < 50 cells. Supplementary Figure S7. C Lahsnig et al. B. Metastases of different sizes (percent of total).

98 views • 1 slides

Supplementary Figure

110 views • 1 slides

Supplementary Figure

Supplementary Figure. PVY CP. PLRV CP. PVA CI. Fig. S1. PVY CP-F. (a). PVY CP -R. PLRV CP-F. PLRV CP-R. attB2. PVA CI-F. (b). PLRV CP. PVY CP. PVA CI. PVA CI-R. attB1. 600bp. P35S. 600bp. Intron. T35S. Kan. (c). LB. RB. pK7GWIWG2(I). Intron R. Intron F. P35SR. T35SF.

186 views • 7 slides

Supplementary Figure

Supplementary Figure. Body weight gain (g). Days. Supplementary Figure. Body weight gain in control and diabetic rats. Rats were fed a chow or high-fat diet for 21 days, with STZ injected at varying doses at day 14. n = 4 - 11 per group.

105 views • 1 slides

Supplementary Figure

Supplementary Figure. Supplementary Figure

90 views • 1 slides

Supplementary Figure 1

A. *. A average weight [g]. A average weight [g]. CR. CR. Control. Control. T ime of experiment [week s ]. T ime of experiment [week s ]. *p<0,05. B. Supplementary Figure 1.

79 views • 1 slides

Supplementary Figure 2

HCT116. HCT116. NT. SN. NT. SN38. 5. 1.6. LC3 labelling. 4. 1.2. SN38 IC50 (nM). 3. 0.8. LC3 spots/cell. LC3. 0.4. 2. HCT116. Actin. 0. 1. Clonogenic assay. SN38. siCT. siATG5. siATG7. 0. shLUC. shMAPK14. HCT116. NT. SN38. 3. LC3. Cytotoxic assay. 100. GAPDH.

109 views • 1 slides

Supplementary Figure 1.

86 views • 1 slides

Figure S4 supplementary

Figure S4 supplementary. h igh. low.

91 views • 1 slides

Supplementary Figure 1

Bemmo et al. Supplementary Figure 1.

86 views • 1 slides

Supplementary Figure 2

Supplementary Figure 2.

65 views • 1 slides

Supplementary Fig. S7

Control ZNF313 p21 WAF1. Intermediate deep cerebellar nucleus. Embryonic day 18 Postnatal day 7 Postnatal day 30. Cerebellar lobe. Cerebellar lobe. Purkinje cell layer Postnatal day 30. Lateral vestibular nucleus Postnatal day 30. Normal Breast BT20

108 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. D. B. A. C. 3 (51 ～ 75%). 2 (26 ～ 50%). 1 (1 ～ 25%). 4 (76 ～ 100%). E. F. G. H. 3 (strong). 2 (moderate). 0 (negative). 1 (weak). Supplementary Figure 2. A. SW480. HT29. C. D. ANGPTL2/GAPDH. ANGPTL2/GAPDH. ANGPTL2/GAPDH. E. B. F. SW480. HT29.

115 views • 3 slides

More Related